ArticleFrontiers in veterinary science2025
Role of miR-144-5p in modulating lipid metabolism and potentially alleviating obesity via the PGC-1α/AMPK pathway.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sanzi Sijun Formula Alleviates Lipotoxic Liver Injury in Metabolic Dysfunction-Associated Steatotic Liver Disease via AMPK/SIRT1 Signaling Pathway.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: MiR-144-5p is differentially expressed in plasma exosomes from Bactrian camels of varying body sizes, with GO and KEGG analyses indicating that its target genes play crucial roles in lipid metabolism. PGC-1α, confirmed as a key target through RNA pull-down and dual-luciferase reporter assays, is a significant regulator of this process. This study aims to investigate the impact of miR-144-5p on lipid metabolism in a mouse model of high-fat diet (HFD)-induced obesity to elucidate the mechanistic pathways involved. Methods: Male C57BL/6 mice were assigned to groups and fed either a control diet or an HFD for 12 weeks, which was followed by a 3-week intervention with miR-144-5p. Various metabolic parameters and gene expressions were evaluated to determine the effects of this treatment. Results: The treatment significantly reduced diet-induced adiposity and decreased inflammatory responses. Additionally, it inhibited PGC-1α expression in the liver tissue of HFD-fed mice. There was an increase in CPT1 activity and fatty acid β-oxidation rate, along with the downregulation of FASN mRNA expression and the upregulation of CPT1 and ACOX1 expression, promoting fatty acid oxidation. Discussion: These findings suggest that miR-144-5p exerts anti-obesity effects by enhancing fatty acid oxidation, likely through modulation of the PGC-1α/AMPK signaling pathway. This study provides new insights into potential miRNA-based therapeutic strategies for obesity and related metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.